This Article Full Text (PDF) All Versions of this Article: 0269881106072341v1 21/7/718    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hwang, R. Articles by Kennedy, J. L. Search for Related Content PubMed PubMed Citation Articles by Hwang, R. Articles by Kennedy, J. L. Social Bookmarking                   What's this?

Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response

Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Takahiro Shinkai

Department of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan

Vincenzo De Luca

Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Xingqun Ni

Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada

Steven G. Potkin

Brain Imaging Center, University of California, Irvine, USA

Jeffrey A. Lieberman

University of North Carolina Medical School, North Carolina, USA

Herbert Y. MeLtzer

Psychiatric Hospital at Vanderbilt University, Nashville, USA

James L. Kennedy

Neurogenetics Section, Centre for Addiction and Mental Health, University of Toronto, Toronto, Canada, james_kennedy{at}camh.net

Dopamine D1 receptors (D1) in the prefrontal cortex have been implicated in the modulation of cognitive processes as well as both positive and negative symptoms of schizophrenia. Therefore pharmacologic agents with potent D1 effects such as clozapine may influence the symptoms of schizophrenia (SCZ). Genetic variation in the D1 receptor gene (DRD1) may help to explain some of the variability in patient response to antipsychotics (APs). This study investigates the effect of four single nucleotide polymorphisms (SNPs) in DRD1 on clozapine response in two distinct SCZ populations (Caucasian and African American) refractory or intolerant to conventional APs. This study included 183 Caucasian and 49 African American schizophrenics diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (revised third or fourth edition). Genotyping was determined by 5'-exonuclease fluorescence assays. Within each population genotype, allele, allele +/— and haplotype frequencies were compared against dichotomous and quantitative measures of treatment response. Linkage disequilibrium analysis was also performed. In the Caucasian sample, no associations were observed for individual SNP tests. However, a rare three-marker haplotype predicted poor response. In the African American sample, the rs265976 variant and another three-marker haplotype were associated with cLozapine response. Although we did not find an association between the rs4532 SNP (—48 A/G, recognized by a DdeI restriction cut site) and cLozapine response as reported by Potkin et al. (2003), a trend in the same direction was observed as well. Our findings suggest that the rs4532 SNP may have a small effect if any. Further studies in larger, independent samples are required to validate these findings.

Key Words: clozapine • antipsychotics • response • dopamine D1 • association study • pharmacogenetics • schizophrenia

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?